

## WEST Search History

DATE: Friday, August 01, 2003

| <u>Set Name</u>                  | <u>Query</u>                    | <u>Hit Count</u> | <u>Set Name</u> |
|----------------------------------|---------------------------------|------------------|-----------------|
| side by side                     |                                 |                  | result set      |
| <i>DB=USPT; PLUR=YES; OP=ADJ</i> |                                 |                  |                 |
| L6                               | L1 and protease and herpes.clm. | 0                | L6              |
| L5                               | L1 and protease and CMV.clm.    | 0                | L5              |
| L4                               | L1 and protease and CMV         | 29               | L4              |
| L3                               | L1 and protease                 | 66               | L3              |
| L2                               | preventing apoptosis.clm.       | 8                | L2              |
| L1                               | preventing apoptosis            | 90               | L1              |

END OF SEARCH HISTORY

**WEST**☐ **Generate Collection** **Print**

L2: Entry 1 of 8

File: USPT

Feb 25, 2003

US-PAT-NO: 6524821

DOCUMENT-IDENTIFIER: US 6524821 B1

TITLE: Anti-apoptotic compositions comprising the R1 subunit of herpes simplex virus ribonucleotide reductase or its N-terminal portion; and uses thereof

DATE-ISSUED: February 25, 2003

## INVENTOR-INFORMATION:

| NAME            | CITY     | STATE | ZIP CODE | COUNTRY |
|-----------------|----------|-------|----------|---------|
| Langelier; Yves | Montreal |       |          | CA      |
| Massie; Bernard | Montreal |       |          | CA      |

US-CL-CURRENT: 435/69.1; 435/183, 435/235.1, 435/320.1, 530/350, 536/23.1

## CLAIMS:

What is claimed is:

1. A method for preventing apoptosis in vitro, induced in a cell by an apoptotic component other than Herpes simplex virus ribonucleotide reductase without the N-terminal 357 amino acids thereof, which comprises the step of submitting said cell to an anti-apoptotic treatment with an anti-apoptotic agent comprising R1 subunit of Herpes simplex virus ribonucleotide reductase enzyme or a nucleic acid encoding said enzyme.
2. A method as defined in claim 1, which further comprises the step of co-administering another anti-apoptotic agent.
3. A method as defined in claim 1, wherein said anti-apoptotic treatment comprises achieving in said cell a concentration of about 0.005% R1 subunit of Herpes simplex virus ribonucleotide reductase enzyme with regard to the amount of total cellular proteins.
4. A method as defined in claim 1, wherein said apoptotic component involves TNF-.alpha., Fas or Caspase 8 activation in said cell.